中國Accelerated Patent ExaminationChina Patent OfficeCNIPAHong KongInventionsPrioritized Examination
2023年1月4日

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

by
張佩雯女士
車李曉芸女士

New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To be eligible, the patent application must be:

  1. an invention application filed directly in China or via national phase entry into China in the substantive examination stage;
  2. filed electronically;
  3. the invention belongs to a qualified technical field, such as internet, big data, cloud computing, biotechnology, environment protection, high-end technology manufacturing, new materials, energy conservation, and more—check out this document (Chinese only) to see the eligible IPC codes; and
  4. the applicant or at least one co-applicant must be (1) a Hong Kong permanent resident or (2) a company established under Companies Ordinance in Hong Kong or a legal entity or organization of other types in Hong Kong.

To request a prioritized examination, the applicant will need to submit a request form along with other required documents to the CNIPA at one of the representative offices in Guangdong or Shenzhen, by mail or in person. Of particular note, applicants must submit information about the existing technology in the field, i.e., known prior art, not unlike an Information Disclosure Statement (IDS) in the US. The applicant must appoint an agency to file the request for prioritized examination unless they have a permanent residence or business office in Mainland China.

Additional Notes:

  • Same Day Invention + UM Applications will generally not receive prioritized examination
  • All foreign language materials must be translated into Chinese
  • There is no charge for this service
  • Restrictions may apply

EIP Comments

This ability to get prioritized examination is great news for Hong Kong permanent residents and Hong Kong companies. Hong Kong could become a very strategic location for international businesses thinking of setting up an office in Asia, especially if being able to get Chinese patents granted quickly is important. International companies can also consider partnering with Hong Kong entities, since co-applicants including a Hong Kong applicant can also enjoy this new pilot program.

If you think you may be eligible for this “fast track” route and would like some help, please feel free to contact us. Our Shenzhen entity Eagle IP (Shenzhen) is a registered Chinese patent agency and we can assist with applications under this pilot program.

Official details (Chinese only) can be found here: https://www.cnipa.gov.cn/art/2022/12/23/art_53_180967.html

For more details about prioritized examination, feel free to send us an email at [email protected].

Eagle IP is a top-tier boutique patent firm with a unique mix of experienced US and Chinese patent professionals with significant cross-border knowledge and experience. Our technically expertise covers wide range of technologies including, but not limited, to life sciences, biotechnology, medicine, pharmaceuticals, material and environmental science, chemistry and consumer electronics. We have years of experiences in drafting and prosecuting patent applications involving biological deposits, sequence listings, small and large molecules, drug discovery and development, material science, software and engineering, and many others.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Introducing the New USPTO Cancer Moonshot Expedited Examination Pilot Program

2023年1月10日
Starting from February 1, 2023, the USPTO will begin the new Cancer Moonshot Expedited Examination Pilot Program that advances out-of-turn applications that are directed to oncology or smoking cessation. This new program will replace the Cancer Immunotherapy Pilot Program that has been in place since 2016, and covers more technologies than only cancer immunotherapies. Applications […]

Stealing Trade Secrets: How the Chinese Court Criminally Sentences Employees that Steal Trade Secrets - 2019 China’s Top 50 Representative IP Cases

2020年6月11日
The theft of trade secrets has always been a deep concern of foreign companies thinking of doing business in China, whether it be sharing protocols with a manufacturing partner, providing technology details to a potential investor, or sharing results from an R&D collaboration. How can businesses ensure that employees do not steal secrets and share […]
China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

2020年4月23日
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]

我們過去活動

Top crossarrow-right